Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Company Deals

Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access

Fineline Cube Jul 15, 2026
Company Deals

Insilico Medicine and Bora Pharmaceuticals Forge $2.5B Strategic Alliance to Pioneer AI-Driven Drug R&D

Fineline Cube Jul 15, 2026
Company Deals

CR Pharmaceutical Commercial and Innovent Biologics Forge Strategic Partnership to Build Integrated Health Management Ecosystem

Fineline Cube Jul 14, 2026
Company Deals

Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC

Fineline Cube Jul 14, 2026
Policy / Regulatory

China’s State Council Unveils “15th Five-Year” National Health Plan with Strong Support for Innovative Therapeutics and AI Integration

Fineline Cube Jul 14, 2026
Company Drug

Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H/dMMR Colon Cancer

Fineline Cube Jul 15, 2026
Company Drug

Kelun-Biotech’s Sacituzumab Tirumotecan Achieves World’s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC

Fineline Cube Jul 15, 2026
Company Deals

Affinity (Shanghai) Secures Over RMB 400 Million in Series B2 Financing to Advance Oncology Drugs

Fineline Cube Dec 2, 2024

Affinity (Shanghai), the parent company of Shanghai Affinity Biopharmaceutical Co., Ltd., has reportedly raised upwards...

Company Deals Hospital

Abogen Biosciences and Ruijin Hospital Launch Ruijin Abogen Nucleic Acid Drug Research Institute

Fineline Cube Dec 2, 2024

China-based nucleic acid drug developer Suzhou Abogen Biosciences and Ruijin Hospital, a comprehensive Class 3A...

Company Drug

Henlius Biotech Initiates US Commercial Supply of Hanquyou, Biosimilar to Herceptin

Fineline Cube Dec 2, 2024

Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the initiation of commercial supply of its...

Company Drug

ImmuneOnco Biopharmaceuticals Receives NMPA Approval for Lupus Nephritis Phase II Study

Fineline Cube Dec 2, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541), a China-based biopharmaceutical company, has announced receiving approval from...

Company Drug

Healthgen Biotechnology’s Plant-Made Albumin Breakthrough: A Milestone in Serum Therapy

Fineline Cube Dec 1, 2024

On November 30th, Healthgen Biotechnology Corp. announced a significant research outcome at the 9th Pharmaceutical...

Company

Shanghai Cell Therapy Group’s Second Attempt at HK IPO Receives Green Light from CICC and CCB International

Fineline Cube Dec 1, 2024

Shanghai Cell Therapy Group Co., Ltd., a leading player in China’s cellular medical health sector,...

Company

Nanjing Leads Biolabs Commences IPO Process with Focus on Innovative Therapies

Fineline Cube Nov 30, 2024

Nanjing Leads Biolabs Co., Ltd., a clinical-stage biopharmaceutical company focused on developing innovative therapies for...

Company Drug

XellSmart Bio-Pharmaceutical Achieves Milestone with First Patient Enrollment in Global iPSC Clinical Study for ALS

Fineline Cube Nov 30, 2024

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd., in collaboration with Shanghai East Hospital (Tongji University Affiliated East...

Company Drug

Cutia Therapeutic’s CU-20401 Shows Positive Results in Phase II Subcutaneous Fat Reduction Study

Fineline Cube Nov 29, 2024

China-based dermatology specialist Cutia Therapeutic (HKG: 2487) has revealed a positive readout from its Phase...

Company Deals

OBiO Technology Partners with Hanxin Biotechnology to Advance LNP Delivery System

Fineline Cube Nov 29, 2024

China-based gene therapy Contract Research Organization (CRO) OBiO Technology (Shanghai) Co., Ltd (SHA: 688238) has...

Company Medical Device

NMPA Approves Shenzhen Mindray’s Innovative Dual-Mode Ultrasound Diagnostic System

Fineline Cube Nov 29, 2024

The National Medical Products Administration (NMPA) has granted approval to Shenzhen Mindray Bio-Medical Electronics Co.,...

Company Medical Device

NMPA Approves Hangzhou Ruidi Biotechnology’s Steep Pulse Therapy Equipment for Tumor Treatment

Fineline Cube Nov 29, 2024

China’s National Medical Products Administration (NMPA) has granted approval to Hangzhou Ruidi Biotechnology Co., Ltd...

Company Drug

CDE Expands Care Plan with Approvals for Ractigen’s RAG-17 and Vitalgen’s VGR-R01

Fineline Cube Nov 29, 2024

In a swift succession of actions, China’s Center for Drug Evaluation (CDE) has added two...

Policy / Regulatory

NMPA Drafts Medical Representative Management Measures, Seeks Public Input

Fineline Cube Nov 29, 2024

The National Medical Products Administration (NMPA) has released the “Medical Representative Management Measures (draft proposal)”,...

Company Deals

Daiichi Sankyo Invests RMB 1.1 Billion in New ADC Manufacturing Plant in Shanghai

Fineline Cube Nov 29, 2024

Japanese pharmaceutical company Daiichi Sankyo (TYO: 4568) is significantly increasing its investment in China with...

Company Drug

Jiangsu Kanion Pharmaceutical Gets NMPA Clearance for Oncolytic Virus Product KYS202003A

Fineline Cube Nov 29, 2024

Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced that it has received clinical clearance...

Company Deals

Lingyi Biotechnology and Jolly Pharmaceutical Ink Comprehensive Collaboration Agreement

Fineline Cube Nov 29, 2024

China-based gene therapy specialist Lingyi Biotechnology Co., Ltd has entered into a comprehensive collaboration agreement...

Company Drug

Sichuan Biokin Pharmaceutical’s BL-M08D1 ADC Receives NMPA Approval for Clinical Trials

Fineline Cube Nov 29, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...

Company Deals

Huadong Medicine Receives FDA Clearance for HDM1005 Clinical Study in Obstructive Sleep Apnea

Fineline Cube Nov 29, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clearance from...

Company Drug

Laekna, Inc. Initiates IND-Enabling Study for Monoclonal Antibody LAE123 in Severe Diseases

Fineline Cube Nov 29, 2024

Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced the initiation of an Investigational New...

Posts pagination

1 … 285 286 287 … 695

Recent updates

  • Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger
  • Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access
  • Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H/dMMR Colon Cancer
  • Kelun-Biotech’s Sacituzumab Tirumotecan Achieves World’s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC
  • CSPC Pharmaceutical Secures Dual NMPA Breakthrough Therapy Designations for HER2-Positive Breast Cancer Combination
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Company Deals

Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access

Company Drug

Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H/dMMR Colon Cancer

Company Drug

Kelun-Biotech’s Sacituzumab Tirumotecan Achieves World’s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.